Condition: Proliferative Diabetic Retinopathy · Diabetic Retinopathy · Diabetic Retinopathy Visually Threatening · Sponsor: Vastra Gotaland Region
Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.
This description comes directly from the study's public registry record.
Imadeddin Abu Ishkheidem, M.D. · +46738744867 · imadeddin.abu.ishkheidem@vgregion.se
Sofia Töyrä Silfverswärd, PhD · +46761283085 · sofia.toyra.silfversward@vgregion.se
Always discuss trial participation with your own doctor first.
| Ögonmottagning Mölndal/SU | Mölndal, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06549023